资讯

AstraZeneca (LSE:AZN) Anselamimab Shows Promise In AL Amyloidosis Despite Missing Main Endpoint
AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...
Zacks Investment Research on MSN17 小时
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...
Applied Clinical Trials Online18 小时
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...
AstraZeneca’s AL amyloidosis drug fails to impress in Phase III
AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III ...